» Articles » PMID: 32366840

Oncogenic Driver Genes and Tumor Microenvironment Determine the Type of Liver Cancer

Overview
Journal Cell Death Dis
Date 2020 May 6
PMID 32366840
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Primary liver cancer (PLC) may be mainly classified as the following four types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), hepatoblastoma (HB), and combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (cHCC-ICC). The majority of PLC develops in the background of tumor microenvironment, such as inflammatory microenvironments caused by viral hepatitis, alcoholic or nonalcoholic steatohepatitis, carbon tetrachloride (CCl), 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), and necroptosis-associated hepatic cytokine microenvironment caused by necroptosis of hepatocytes. However, the impact of different types of microenvironments on the phenotypes of PLC generated by distinct oncogenes is still unclear. In addition, the cell origin of different liver cancers have not been clarified, as far as we know. Recent researches show that mature hepatocytes retain phenotypic plasticity to differentiate into cholangiocytes. More importantly, our results initially demonstrated that HCC, ICC, and cHCC-ICC could originate from mature hepatocytes rather than liver progenitor cells (LPCs), hepatic stellate cells (HSCs) and cholangiocytes in AKT-driven, AKT/NICD-driven and AKT/CAT-driven mouse PLC models respectively by using hydrodynamic transfection methodology. Therefore, liver tumors originated from mature hepatocytes embody a wide spectrum of phenotypes from HCC to CC, possibly including cHCC-ICC and HB. However, the underlying mechanism determining the cancer phenotype of liver tumors has yet to be delineated. In this review, we will provide a summary of the possible mechanisms for directing the cancer phenotype of liver tumors (i.e., ICC, HCC, and cHCC-ICC) in terms of oncogenic driver genes and tumor microenvironment. Moreover, this study initially revealed the cell origin of different types of liver cancer.

Citing Articles

Identifying potential signatures of immune cells in hepatocellular carcinoma using integrative bioinformatics approaches and machine-learning strategies.

Liu X, Pan B, Ding J, Zhai X, Hong J, Zheng J Immunol Res. 2025; 73(1):46.

PMID: 39904830 DOI: 10.1007/s12026-024-09585-3.


Analysis of the implication of steroid 5 alpha-reductase 3 on prognosis and immune microenvironment in Liver Hepatocellular Carcinoma.

Lu Y, Liu Z, Zheng Y, Liu X, Liu X, Chen N Ann Med. 2024; 56(1):2408463.

PMID: 39340288 PMC: 11441025. DOI: 10.1080/07853890.2024.2408463.


Thiostrepton as a Potential Therapeutic Agent for Hepatocellular Carcinoma.

Su G, Yang Q, Zhou H, Huang Y, Nie S, Wang D Int J Mol Sci. 2024; 25(17).

PMID: 39273665 PMC: 11395809. DOI: 10.3390/ijms25179717.


Non-genetic heterogeneity and immune subtyping in breast cancer: Implications for immunotherapy and targeted therapeutics.

Hassan M, Tutar L, Sari-Ak D, Rasul A, Basheer E, Tutar Y Transl Oncol. 2024; 47:102055.

PMID: 39002207 PMC: 11299575. DOI: 10.1016/j.tranon.2024.102055.


Phase separation of RNF214 promotes the progression of hepatocellular carcinoma.

He Z, He K, Cai S, Zhang R, Shao Z, Wang S Cell Death Dis. 2024; 15(7):483.

PMID: 38969650 PMC: 11226663. DOI: 10.1038/s41419-024-06869-2.


References
1.
Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler S, Zeleznik-Le N . FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis. Hepatology. 2014; 61(1):214-26. PMC: 4280291. DOI: 10.1002/hep.27402. View

2.
Connell L, Harding J, Shia J, Abou-Alfa G . Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Chin Clin Oncol. 2016; 5(5):66. DOI: 10.21037/cco.2016.10.02. View

3.
Yamamoto M, Xin B, Watanabe K, Ooshio T, Fujii K, Chen X . Oncogenic Determination of a Broad Spectrum of Phenotypes of Hepatocyte-Derived Mouse Liver Tumors. Am J Pathol. 2017; 187(12):2711-2725. DOI: 10.1016/j.ajpath.2017.07.022. View

4.
Lee J, Heo J, Libbrecht L, Chu I, Kaposi-Novak P, Calvisi D . A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12(4):410-6. DOI: 10.1038/nm1377. View

5.
Fan B, Malato Y, Calvisi D, Naqvi S, Razumilava N, Ribback S . Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122(8):2911-5. PMC: 3408746. DOI: 10.1172/JCI63212. View